TORONTO, Nov. 2 /PRNewswire-FirstCall/ - ChondroGene Limited announced today that Dr. K. Wayne Marshall, President and CEO, will be presenting at the upcoming Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York at 11:55 a.m. on November 7, 2005. Dr. Marshall will provide an update and status report on the Company’s lead product, a blood-based colon cancer test, as well as give a general corporate update.
The presentation will be webcast live and may be accessed on ChondroGene’s website at www.chondrogene.com or on the Rodman & Renshaw website at www.rodmanandrenshaw.com. The presentation will be archived for a period of time after the event.
About ChondroGene
-----------------
ChondroGene is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle, to detect and stage virtually any disease or medical condition from a simple blood sample. ChondroGene is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on ChondroGene, visit www.chondrogene.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.
ChondroGene Limited
CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234,wmarshall@chondrogene.com; Bruno Maruzzo, Corporate Development, (416)650-0060 x237, bmaruzzo@chondrogene.com
